Autopsy report · NCT05733611

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

“Business reasons.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 2 years 2 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Replimune, Inc.

Sponsor type

Industry

Conditions

Refractory Metastatic Colorectal Cancer; pMMR; MSS

Interventions

RP2; RP3; atezolizumab; bevacizumab

Participants

5

Sites

2

Countries

United States

Trials that died the same way

• Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
  “For business reasons.” (85% match in meaning)
• Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
  “Due to business reasons” (82% match in meaning)
• StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns
  “Business Reason” (81% match in meaning)
• First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
  “Business/Commercial Reasons” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.